The group's principal activity is to discover and develop novel cancer therapeutics. It aims to be a leader in developing innovative treatments that address important unmet medical needs in cancer. It currently has multiple products in development including ADH-1 (ExherinTM), eniluracil and sodium thiosulfate (STS). ADH-1, its lead biotechnology compound selectively targets N-cadherin, a protein present on certain tumor cells and established blood vessels that feed solid tumors. Eniluracil, a dihydropyrimidine dehydrogenase (DPD) inhibitor, is being developed to enhance the therapeutic value and effectiveness of 5-FU, one of the most widely used oncology drugs in the world. STS, a drug from its specialty pharmaceuticals pipeline, protects against the disabling hearing loss that can often result from treatment with platinum-based chemotherapy drugs. The company has a diversified portfolio of unique preclinical and clinical-stage cancer compounds and a management team with expertise in identifying, developing and commercializing novel cancer therapeutics.
http://www.adherex.com/
